| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
In U251 glioblastoma cells, MOPIPP (10 μM; 48 h) causes cellular vacuolization but does not result in cell death; these cells display traits of late endosomes[1][2]. MOPIPP (10 μM; 24 h) prevents autophagosome fusion with lysosomes and causes an increase in LC3 fluorescence correlated with autophagosome number[1]. The quantities of exosomal marker proteins in the vesicle fractions recovered from 293T cells are increased by MOPIPP (10 μM; 24 h)[2]. In glioblastoma and other cancer cell lines, MOPIPP (10 μM; 24 h and 5 h, respectively) produces methuosis, a type of non-apoptotic cell death, and causes early abnormalities of glucose uptake and glycolytic metabolism[3]. Phosphorylation of c-Jun, Bcl-2, and Bcl-xL results from the selective activation of the JNK1/2 stress kinase pathway by MOMIPP (10 μM; 4 h and 24 h)[3].
|
|---|---|
| ln Vivo |
In female Swiss Webster mice, MOMIPP (80 mg/kg; ip; single dose) easily crosses the blood-brain barrier. In female NCR-Foxn1 mice, MOMIPP (80 mg/kg; ip; every 24 h; 15 d) effectively inhibits the growth of intracerebral glioblastoma xenografts[3].
|
| Animal Protocol |
Animal/Disease Models: Intracerebral xenograft model in NCR-Foxn1 mice (female, 7-8 weeks, injected with U251- LUC cells)[3]
Doses: 80 mg/kg Route of Administration: intraperitoneal (ip) injection; every 24 hrs (hours) for 15 days; monitored tumor progression by BLI on the days 7, 11, 15 Experimental Results: Dramatically inhibited tumor progression. |
| References |
|
| Molecular Formula |
C20H20N2O2
|
|---|---|
| Molecular Weight |
320.385004997253
|
| Exact Mass |
320.152
|
| CAS # |
1485521-76-3
|
| Related CAS # |
MOMIPP;1363421-46-8
|
| PubChem CID |
76332072
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
445
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC1=C(C2=C(N1)C=CC(=C2)OC)/C=C/C(=O)C3=CC=NC=C3
|
| InChi Key |
AKHPVAVYPREXID-SOFGYWHQSA-N
|
| InChi Code |
InChI=1S/C20H20N2O2/c1-3-4-18-16(6-8-20(23)14-9-11-21-12-10-14)17-13-15(24-2)5-7-19(17)22-18/h5-13,22H,3-4H2,1-2H3/b8-6+
|
| Chemical Name |
(E)-3-(5-methoxy-2-propyl-1H-indol-3-yl)-1-pyridin-4-ylprop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1212 mL | 15.6060 mL | 31.2120 mL | |
| 5 mM | 0.6242 mL | 3.1212 mL | 6.2424 mL | |
| 10 mM | 0.3121 mL | 1.5606 mL | 3.1212 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
